19 October 2022 - NICE has published evidence-based recommendations on the use of fostamatinib disodium hexahydrate for the treatment of adults with chronic refractory chronic immune thrombocytopenia.

Fostamatinib disodium hexahydrate is recommended as an option for the treatment of adults with refractory chronic immune thrombocytopenia only if:

• They have previously had a thrombopoietin receptor agonist (TPO‑RA), or the use of a TPO‑RA is unsuitable
• Grifols provides fostamatinib disodium hexahydrate according to the commercial arrangement

Read NICE technology appraisal guidance